This article is a correction to:
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
Federico La Manna1,2
Marta De Menna1
Nikhil Patel3
Sofia Karkampouna1Maria Rosaria De Filippo1,4Irena Klima1
Peter Kloen5Lijkele Beimers6George N. Thalmann7Rob C. M. Pelger2
Estela Jacinto3
Marianna Kruithof-de Julio1,7*- 1Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland
- 2Department of Urology, Leiden University Medical Center, Leiden, Netherlands
- 3Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, NJ, United States
- 4Institute of Pathology and Medical Genetics, University Hospital Basel, University of Basel, Basel, Switzerland
- 5Department of Orthopedic Trauma Surgery, Academic Medical Center, Amsterdam, Netherlands
- 6Department of Orthopedic Surgery, MC Slotervaart, Amsterdam, Netherlands
- 7Department of Urology, Inselspital, Bern University Hospital, Bern, Switzerland
A Corrigendum on
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
By La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L, Thalmann GN, Pelger RCM, Jacinto E and Kruithof-de Julio M (2020). Front. Oncol. 10:1012. doi: 10.3389/fonc.2020.01012
An author name was incorrectly spelled as “Maria De Filippo”. The correct spelling is “Maria Rosaria De Filippo”.
In the published article, there was also an error in affiliation 1. Instead of “Department of BioMedical Research, University of Bern, Bern, Switzerland”, it should be “Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland”.
There was also an error in the text. The concentration and administration schedule of Rapalink-1 reported for the in vivo experiment was not correct. The error appeared both in the “Materials and Methods” and in the “Results” sections, where it is incorrectly reported as “1.5 mg/g [ … ] every 5 days” and “1.5 mg/g/6 days”, respectively. Figure 5C in the original article reported the correct administration schedule.
A correction has been made to the “Materials and Methods” section, “Animals Maintenance and in vivo Experiment” sub-section:
“Group 1 received 3.5 μl/g of vehicle (20% DMSO, 40% PEG-300 and 40% PBS) i.p. once a week while group 2 received Rapalink-1 (1.5 mg/Kg) resuspended in vehicle, i.p. every 5-7 days.”
A correction of the same error has been made to the “Results” section, “Treatment of LAPC9 in vivo With Rapalink-1 Delays Tumor Growth” sub-section, paragraph 2:
“We then assessed the effect of Rapalink-1 (1.5 mg/Kg/5-7 days) in vivo on LAPC9 PDX model, comparing the treatment to vehicle only, a schematic of treatment schedule is reported (Figure 5C).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: bone metastasis, PDX, mTOR, disulfiram, prostate cancer, ALDH
Citation: La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L, Thalmann GN, Pelger RCM, Jacinto E and Kruithof-de Julio M (2021) Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. Front. Oncol. 11:650623. doi: 10.3389/fonc.2021.650623
Received: 07 January 2021; Accepted: 15 January 2021;
Published: 03 February 2021.
Edited and reviewed by: Maria Teresa Valenti, University of Verona, Italy
Copyright © 2021 La Manna, De Menna, Patel, Karkampouna, De Filippo, Klima, Kloen, Beimers, Thalmann, Pelger, Jacinto and Kruithof-de Julio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marianna Kruithof-de Julio, bWFyaWFubmEua3J1aXRob2ZkZWp1bGlvQGRibXIudW5pYmUuY2g=